Pulmonary hemorrhage with hematuria: do not forget IgA nephropathy

Kemi Oluwole¹, Linda Esuzor¹, Oluwafisayo Adebiyi¹, Chike Nzerue², Marquetta Faulkner², Ebele Umeukeje³ and Paisit Paueksakon⁴

¹Department of Medicine, Meharry Medical College, Nashville, TN, USA, ²Renal Division, Department of Medicine, Meharry Medical College, Nashville, TN, USA, ³Vanderbilt University School of Medicine, Nashville, TN, USA and ⁴Department of Pathology, Vanderbilt University School of Medicine, Nashville, TN, USA

Correspondence and offprint requests to: Chike Nzerue; E-mail: cnzerue@mmc.edu

Abstract
IgA nephropathy is the commonest cause of glomerulonephritis worldwide, and is usually a renal-limited disease. In rare cases, IgA nephropathy may also present with a pulmonary–renal syndrome in which pulmonary hemorrhage is a critical feature. Patients presenting with IgA nephropathy and pulmonary hemorrhage have high morbidity and are at high risk for mortality unless rapid immunosuppressive therapy is instituted. We present a case of IgA nephropathy complicated by pulmonary hemorrhage in which immunosuppressive therapy led to a good outcome, and review the literature on similar cases and the outcome of therapy.

Keywords: IgA nephropathy; immunosuppressive therapy; pulmonary hemorrhage

Background
IgA nephropathy is the commonest cause of glomerulonephritis worldwide. Patients with IgA nephropathy seldom show evidence of extra renal disease. It may present with asymptomatic microscopic or macroscopic hematuria, nephritic syndrome, nephrotic syndrome, with or without acute kidney injury. Pulmonary hemorrhage as a presentation of IgA nephropathy is distinctly rare, with only a handful of cases reported so far. These cases display disparate clinical and prognostic features. In this report, we describe a 44-year-old man who presented to the hospital with severe pulmonary hemorrhage and hematuria. His renal biopsy showed IgA nephropathy. This patient had an excellent response to immunosuppressive therapy.

Case report
A 44-year-old Bangladeshi man was admitted to hospital with a history of cough, hemoptysis and dyspnea of 1-day duration. He had previously been healthy until he developed coryza symptoms about 1 week prior to presentation. There was no history of chronic cough, weight loss, night sweats or recent travel outside the USA. The patient had smoked half a pack of cigarettes per day for 15 years but denied a history of exposure to any environmental or industrial exposure to any agents with known pulmonary toxicity. He denied passage of cola-colored urine or gross hematuria. His medications were bismuth subsalicylate for gastroesophageal reflux disease and daily multivitamins.

On examination, his vital signs showed a blood pressure of 143/81 mmHg, pulse of 90 beats/min, temperature of 37°C and respiratory rate of 20. Cardiac examination was normal, but diffuse pulmonary rales were heard in both lung fields on chest auscultation. The rest of his physical examination was normal. The hematocrit was 44% and hemoglobin was 12 g/dL. The white cell count was 4.5 k/mm³, platelet of 196 k/mm³ and a prothrombin time with a normalized international ratio of 0.96. His blood urea nitrogen was 19 mg/dL (6.78 mmol/L) and serum creatinine was 0.96 mg/dL (84.48 mmol/L). Urinalysis was significant for 3+ blood, and >50 rbc/hpf with dysmorphic red cells and 2+ protein. Serologies for antineutrophil cytoplasmic antibodies (ANCA), antinuclear antibodies (ANA), rheumatoid factor, antiglomerular basement membrane antibody (anti-GBM), hepatitis B and C and viruses influenza A and B, adenovirus, enteroviruses, herpes simples I and II, cytomegalovirus, Coxiella burnetti, Mycoplasma pneumonia were all negative. A tuberculin skin test was negative. Sputum cultures for bacterial, fungal and mycobacteria were negative.

A CT scan of the chest with contrast (Figure 1) showed diffuse alveolar bilateral patchy infiltrates, with some emphysematous changes. The lung infiltrates had a ground glass appearance. The patient was admitted to the intensive care unit for closer monitoring, and started on empiric antibiotic therapy for possible pneumonia to
exclude Goodpasture’s syndrome in view of hemoptysis and hematuria. Further laboratory tests including ANA, anti-GBM IgG, complements, viral hepatitis screen, ESR, CRP, VWF, ANCA, sputum AFB ×3 and coagulation panel, were all within normal limits. An upper gastrointestinal endoscopy to investigate hemocult-positive stool did not reveal any active evidence of gastro-intestinal bleeding.

He continued to have massive (>500 mL/day) hemoptysis and hematuria with subsequent decline in the hematocrit necessitating transfusion of a total of 3 units of packed red cells. He underwent bronchoscopy and bronchoalveolar lavage which showed the presence of hemosiderin-laden macrophages and bloody exudate. To establish the cause of the pulmonary-renal presentation of this patient, a kidney biopsy was done.

Renal biopsy (Figure 2) showed mesangial proliferative glomerulonephritis with IgA deposition. The patient was started on intravenous cyclophosphamide 1 g and prednisone 60 mg daily. Over a 4-day period, his hemoptysis gradually resolved, and hemoglobin and hematocrit stabilized at 10.9 gm/dL and 32.1%, respectively. The patient was then started on intravenous cyclophosphamide infusion 1 gm monthly with daily oral prednisone tapered off over an additional 2-month interval. There has been no recurrence of hemoptysis and the patient has since stopped smoking (Table 1).

Discussion

While IgA nephropathy is the commonest cause of primary glomerulonephritis worldwide, pulmonary hemorrhage occurring in patients with IgA nephropathy is distinctly rare, and only 13 cases have so far been reported [1–9]. Our patient’s clinical presentation was comparable with the other 13 cases of IgA nephropathy with pulmonary hemorrhage reported previously in the literature, as shown in Table 2. These cases differ in terms of patient survival, renal function, use of immunosuppressive therapy and whether or not plasmapheresis was used. Interestingly, until recently, most of the reports have been in adults, but a recent report shows that this clinical entity can also occur in children, in a form distinct from Henoch–Schönlein purpura [2].

When pulmonary hemorrhage occurs with IgA nephropathy, other entities that cause pulmonary–renal syndrome such as vasculitides (especially Henoch–Schönlein purpura), Goodpasture’s syndrome, systemic lupus erythematosus as well as co-existing pulmonary tuberculosis must be excluded.

Of the treated patients, four received intravenous methylprednisolone and oral cyclophosphamide [1–6, 8]. Two patients received plasmapheresis [3, 4]. The precise duration of immunosuppressive therapy remains to be determined. While Medcalf et al. [1] suggest that immunosuppressive therapy is of no benefit, our case and others [1–6, 8] suggest that immunosuppressive therapy with or without plasmapheresis may be life-saving. Our patient received a 6-month course of cyclophosphamide and daily steroids which were tapered off after another 2 months. Renal manifestations and prognosis showed significant heterogeneity in reported cases, ranging from hematuria to acute kidney injury and irreversible chronic
kidney disease requiring hemodialysis. Three patients in
the series became dialysis dependent [1–3]. While four
patients died [1, 7], others survived with therapy.

Though the precise pathogenesis of pulmonary hemor-
rhage in IgA nephropathy is unknown, three putative
mechanisms have been suggested. Firstly, pulmonary he-
morrhage may be a non-specific alveolar capillary
response to injury triggered by the IgA immune response
to associated (synpharyngitic) upper respiratory tract in-
fected. Consistent with this suggestion is the report of a
patient with IgA nephropathy on renal replacement
therapy who developed recurrent bloody peritoneal dialy-
sate during respiratory tract infection [10]. Secondly, pul-
monary hemorrhage in IgA nephropathy may be due to
alveolar capillary damage due to anti-glomerular base-
ment membrane antibody (anti-GBM) attack.

Table 2. Case reports of other cases of pulmonary hemorrhage in patients with IgA nephropathy

| Case reports | Age, sex at Dx | Renal function at diagnosis | Pulmonary hemorrhage diagnosis | Treatment received/duration | Outcome |
|--------------|---------------|----------------------------|-----------------------------|-----------------------------|---------|
| 1. Medcalf et al. [1] | 20 M | Hematuria | Clinical | No treatment received | 1. Resolved Hemoptysis 2. Persistence of hematuria/proteinuria |
| 2. Medcalf et al. [1] | 67 M | ARF | Clinical | Methylprednisolone/ cyclophosphamide of unknown duration | 1. Resolved hemoptysis 2. Dialysis dependent |
| 3. Medcalf et al. [1] | 75 M | ESRD | Clinical | Methylprednisolone/ cyclophosphamide | Death |
| 4. Poyyapakkam Srivaths et al. [2] | 14 M | ARF | Hematuria 1. Clinical 2. Lung biopsy | 1. Hemodialysis 2. Methylprednisolone/ cyclophosphamide monthly ×6 cycles 3. Weekly methotrexate ×1 year and pulse steroid | 1. Resolved hemoptysis 2. Dialysis dependent |
| 5. Devanand Anatham et al. [3] | 20 M | ESRD | 1. Bronchioalveolar lavage 2. Lung biopsy | 1. Methylprednisolone with plasma exchange initially ×3 days 2. Oral steroid with cyclophosphamide for unknown duration | 1. Resolved Hemoptysis 2. Dialysis dependent |
| 6. Bekele Afessa et al. [4] | 66 M | ARF | Hematuria | Clinical | 1. Methylprednisolone ×3 months 2. Plasmapheresis thrice weekly ×3 weeks | 1. Resolved hemoptysis 2. Persistence of hematuria/proteinuria 3. CKD |
| 7. Mac-Moune Lai et al. [5] | 45 M | Hematuria | 1. Clinical 2. Lung biopsy | Methylprednisolone ×1 week | Death |
| 8. Mac-Moune Lai et al. [5] | 29 F | CRF | 1. Clinical 2. Lung biopsy | None | Death |
| 9. Mac-Moune Lai et al. [5] | 43 F | Normal | 1. Clinical 2. Lung biopsy | None | Death |
| 10. Yuichiro Endo et al. [6] | 59 M | Normal | Bronchioalveolar lavage Clinical | Methylprednisolone and cyclosorpin for unknown duration Empiric antibiotics for systemic infection | Unknown |
| 11. Chatchai Keeprala MD et al. [7] | 53 M | ARF | Hematuria | Bronchioalveolar lavage Clinical | Methylprednisolone and cyclophosphamide for unknown duration Complete resolution of hemoptysis, hematuria and renal failure |
| 12. Fung and Churchill et al. [8] | 36 M | ARF | Hematuria | Bronchioalveolar lavage | Complete resolution of hemoptysis, hematuria and renal failure |
| 13. Travis et al. [9] | Unknown | Unknown | Unknown | Unknown | Unknown |

Table 1. Laboratory values

| Variable | Admission | Day 2 | Day 3 | Day 4 | Discharge |
|----------|-----------|-------|-------|-------|-----------|
| White cell count (K/mm³) | 4500 | 5800 | 15600 | 13800 | 11000 |
| Hemoglobin (g/dL) | 14.2 | 11.6 | 11.4 | 11.1 | 10.9 |
| Hematocrit (%) | 44.3 | 35.9 | 34.4 | 33.1 | 32.1 |
| Platelets (K/mm³) | 196 | 143 | 164 | 180 | 197 |
| Prothrombin time | 0.96 | 1.16 | 1.12 | — | 1.13 |
| Sedimentation rate | 4 | — | — | 2 | — |
| ANA | — | Negative | — | — | — |
| ANCA | — | <4 | — | — | — |
| Anti-GBM | — | 0 | — | — | — |
| Sodium (mmol/L) | 141 | 140 | 140 | 137 | 139 |
| Potassium (mmol/L) | 3.6 | 4.1 | 3.9 | 3.8 | 3.8 |
| Urea nitrogen (mmol/L) | 6.78 | 5.36 | 6.1 | 6.4 | 7.14 |
| Creatinine (umol/L) | 84.9 | 70.7 | 70.7 | 61.9 | 79.6 |
| Hepatitis B | — | Negative | — | — | — |
| Hepatitis C | — | Negative | — | — | — |
Interestingly, Fervenza et al. recently described a patient who developed anti-GBM disease due to IGA antibodies in a patient with Goodpasture’s syndrome [11]. However, no such circulating antibodies have consistently been shown, and IgA deposition in lung biopsy on immunofluorescence is an inconsistent finding [1]. Thirdly, it has also been suggested that pulmonary hemorrhage occurring with IgA is an immune-complex mediated capillaritis [3]. According to this hypothesis, the pulmonary hemorrhage represents a pulmonary manifestation of immune complex activity. Consistent with this notion, some patients with IgAN have shown IgA and C3 depositions in sites distant from the kidney such as skin [12].

When our patient presented with pulmonary hemorrhage and hematuria, other causes of pulmonary renal syndrome were diligently excluded and pulmonary hemorrhage was confirmed with bronchoscopy and bronchial lavage fluid cytology showing hemorrhagic fluid with pigment laden macrophages. In other reported cases, pulmonary capillaritis [2, 3, 5] characterized by the presence of patchy areas of red blood cells and focal fibrin within airspaces and multiple small foci of organizing pneumonia (Masson bodies) were observed. It is interesting to note that none of the patients that received lung biopsy showed deposition of IgA on the alveolar walls. Pulmonary histology in fatal cases involving Henoch–Schönlein purpura has shown a leucocytoclastic vasculitis and IgA deposition along alveolar septa in areas of hemorrhage [13, 14]. Lung biopsy was not done in our case and thus the exact lung pathology could not be confirmed. The patient’s renal biopsy was typical for IgA nephropathy. The absence of rash, lack of joint and abdominal involvement make Henoch–Schönlein vasculitis highly unlikely.

Other lung diseases associated with IgA nephropathy include idiopathic pulmonary hemosiderosis (IPH) [15, 16], IgA immune complex-mediated pneumonitis [17], pulmonary tuberculosis [18] and bronchiolitis obliterans [19]. Though pulmonary hemorrhage can be a rare manifestation of IgA nephropathy, if it is not recognized, it can run a rapidly fatal course. Prompt recognition and appropriate immunosuppressive therapy leads to a good outcome [20]. Our case highlights the fact that IgA nephropathy should be considered in the differential diagnosis of pulmonary hemorrhage. This presentation may also be a reflection of Floege’s suggestion that IgA nephropathy is a dynamic disease and the defects driving this disease may reside outside the kidney [21].

Conflict of interest statement. None declared.

References

1. Medcalf JF, Brownjohn AM, Turney JH. Pulmonary hemorrhage in association with IgA nephropathy. Nephrol Dial Transplant 1996; 11: 1148–1149
2. Srivaths P, Dishop MK, Elibdemir O et al. IgA nephropathy presenting with renal failure and pulmonary hemorrhage. Pediatr Nephrol 2010; 25: 535–538
3. Anantham D, Chan KP, Chua K et al. Pulmonary capillaritis in IgA nephropathy. South Med J 2007; 100: 605–607
4. Afessa B, Cowart RG, Koenig SM. Alveolar hemorrhage in IgA nephropathy treated with plasmapheresis. South Med J 1997; 90: 237–239
5. Lai FM, Li EK, Suen MW et al. Pulmonary hemorrhage. A fatal manifestation in IgA nephropathy. Arch Pathol Lab Med 1994; 118: 542–546
6. Endo Y, Minato H, Taki R et al. Myeloperoxidase-antineutrophil cytoplasmic antibody-negative microscopic polyangiitis with pulmonary hemorrhage and IgA nephropathy. Case Rep Dermatol 2011; 3: 22–27
7. Kreekala C, Changsirikulchai S, Chalermsanyakorn P. Pulmonary hemorrhage with acute renal injury in a patient with IgA nephropathy. J Med Assoc Thai 2009; 92(Suppl 3): S80–S84
8. Fung M, Churchill D, Alexopoulou I et al. IgA nephropathy and pulmonary hemorrhage in an adult. Am J Nephrol 2001; 21: 318–322
9. Travis WD, Colby TV, Lombard C et al. A clinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation. Am J Surg Pathol 1990; 14: 1112–1125
10. Rambousek M, Ritz E, Waldherr R. Recurrent bloody diastole during upper respiratory tract infection in mesangial IgA glomerulonephritis. Nephron 1987; 46: 213
11. Borza DB, Chedid MF, Colon S et al. Recurrent Goodpasture’s disease secondary to a monoclonal IgA1-kappa antibody autoantibody with the alpha1alpha2 chains of type IV collagen. Am J Kidney Dis 2005; 45: 397–406
12. Faille-Kuyper EH, Kater L, Kuijten RH et al. Occurrence of vascular IgA deposits in clinically normal skin of patients with renal disease. Kidney Int 1976; 9: 424–429
13. Kathuria S, Cheifec G. Fatal pulmonary Henoch–Schönlein syndrome. Chest 1982; 82: 654–656
14. Payton CD, Allison ME, Boulton-Jones JM. Henoch Schönlein purpura presenting with pulmonary haemorrhage. Scott Med J 1987; 32: 26–27
15. Kjellman B, Elinder G, Garwicz S et al. Idiopathic pulmonary haemosiderosis in Swedish children. Acta Paediatr Scand 1984; 73: 584–588
16. Ohga S, Takahashi K, Miyazaki S et al. Idiopathic pulmonary haemosiderosis in Japan: 39 possible cases from a survey questionnaire. Eur J Pediatr 1995; 154: 994–995
17. Harland RW, Becker CG, Brandes JC et al. Immunoglobulin A (IgA) immune complex pneumonitis in a patient with IgA nephropathy. Ann Intern Med 1992; 116: 220–222
18. Cohen AJ, Rosenstein ED. IgA nephropathy associated with disseminated tuberculosis. Arch Intern Med 1985; 145: 554–556
19. Hernandez JL, Gomez-Roman J, Rodrigo E et al. Bronchiolitis obliterans and IgA nephropathy. A new cause of pulmonary-renc syndrome. Am J Respir Crit Care Med 1997; 156: 665–668
20. Floege J, Eitner F. Current therapy for IgA nephropathy. J Am Soc Nephrol 2012; 22: 1785–1794
21. Floege J. The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches? Am J Kid Dis 2011; 58: 992–1004

Received for publication: 9.7.12; Accepted in revised form: 12.7.12